Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
14/6 11:50
Novo Nordisk's (NYSE: NVO) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024....